ADIL
Adial Pharmaceuticals, Inc. NASDAQ Listed Jul 27, 2018$5.04
+1.00%
vs $4.99
Mkt Cap $4.8M
52w Low $1.31
39.5% of range
52w High $10.75
50d MA $3.06
200d MA $3.88
P/E (TTM)
—
EV/EBITDA
—
P/B
0.6x
Debt/Equity
0.0x
ROE
-151.2%
P/FCF
-0.5x
RSI (14)
72.70
ATR (14)
$0.55
Beta
1.40
50d MA
$3.06
200d MA
$3.88
Avg Volume
59.6K
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
1180 Seminole Trail · Charlottesville, VA 22901 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | AMC | -2.73 | -1.48 | +45.8% | 1.38 | -0.7% | -1.4% | +1.5% | +16.7% | +28.0% | +14.1% | — |
| Mar 10, 2026 | AMC | -2.10 | -1.81 | +13.8% | 1.83 | +3.8% | +7.7% | -5.1% | +4.8% | -5.6% | +2.2% | — |
| Nov 13, 2025 | AMC | -2.25 | -2.00 | +11.1% | 8.00 | -3.1% | +3.1% | -6.1% | +0.0% | +3.2% | -6.2% | — |
| Aug 13, 2025 | AMC | -0.22 | -0.18 | +18.2% | 10.00 | -5.0% | -2.5% | +0.0% | -2.6% | -2.6% | +0.0% | — |
| May 14, 2025 | AMC | -0.50 | -0.34 | +32.0% | 16.25 | +4.6% | +1.5% | +0.0% | +6.1% | +4.3% | -2.7% | — |
| Mar 4, 2025 | AMC | -0.38 | -0.15 | +60.5% | 18.75 | -1.3% | +2.7% | -2.6% | +0.0% | -4.0% | -12.5% | — |
| Nov 13, 2024 | AMC | -0.50 | -0.38 | +24.0% | 24.75 | +11.1% | +15.2% | -7.0% | -4.7% | +0.0% | +1.0% | — |
| Aug 13, 2024 | AMC | -0.39 | -0.59 | -51.3% | 24.25 | -2.1% | +0.0% | +0.0% | +0.0% | +1.0% | +0.0% | — |
| May 14, 2024 | AMC | -0.51 | -0.68 | -33.3% | 36.00 | -4.9% | -1.4% | -0.7% | +9.9% | -3.2% | -6.7% | — |
| Apr 4, 2024 | AMC | -0.76 | -1.35 | -77.6% | 30.50 | -5.7% | -4.9% | -2.6% | +0.0% | +106.2% | +27.9% | — |
| Nov 14, 2023 | AMC | -1.14 | -1.14 | +0.0% | 54.00 | +0.0% | -1.9% | -3.8% | +2.9% | -1.9% | +5.8% | — |
| Aug 21, 2023 | AMC | -1.50 | -1.33 | +11.3% | 83.75 | -0.3% | -1.8% | +3.3% | -0.3% | +1.2% | -2.6% | — |
| May 12, 2023 | AMC | -3.50 | -2.75 | +21.4% | 187.50 | +6.7% | +6.7% | +0.0% | +3.1% | -3.0% | +0.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 3 | Alliance Global Partners | Initiates | Buy | $11 | $3.34 | $3.41 | +2.1% | +9.0% | +4.4% | +6.6% | +18.5% | -17.1% |
| Sep 30 | Maxim Group | Upgrade | Hold → Buy | — | $8.25 | $8.75 | +6.1% | +6.1% | +5.7% | +8.1% | +0.0% | +0.0% |
| Jul 11 | Brookline Capital | Maintains | Buy → Buy | — | $125.00 | $137.50 | +10.0% | +95.0% | -15.4% | -12.1% | -3.4% | +3.6% |
| Aug 17 | Maxim Group | Downgrade | Buy → Hold | — | $356.25 | $343.75 | -3.5% | +0.0% | +3.5% | +0.0% | -5.1% | -1.8% |
| Oct 13 | Brookline Capital | Maintains | Buy → Buy | — | $2337.50 | $2400.00 | +2.7% | +9.6% | -2.7% | -2.8% | -2.3% | -1.1% |
| Jun 29 | Litchfield Hills | Maintains | Buy → Buy | — | $1706.25 | $1618.75 | -5.1% | -4.4% | -2.3% | -0.8% | +16.2% | -3.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | Coastlands Capital LP10% | — | Buy | 1,233 | $2.75 | $3K | 388,308 | +0.36% | -0.74% |
| Jul 14, 2026 | Coastlands Capital LP10% | — | Buy | 2,000 | $2.65 | $5K | 387,075 | +0.36% | -0.74% |
| Jul 10, 2026 | Coastlands Capital LP10% | — | Buy | 1,700 | $2.70 | $5K | 385,075 | -6.36% | -2.50% |
| Jul 9, 2026 | Coastlands Capital LP10% | — | Buy | 10,053 | $2.79 | $28K | 383,375 | -6.36% | -2.50% |
| Jun 29, 2026 | Coastlands Capital LP10% | — | Buy | 25,000 | $2.60 | $65K | 373,322 | +3.20% | -2.44% |
8-K · 2.02
!! High
Adial Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Adial Pharmaceuticals reported Q2 2026 financial results, with the company's earnings announcement providing investors updated information on operational performance and financial condition for the period ending June 30, 2026.
Aug 17
8-K · 1.01
!!! Very High
Adial Pharmaceuticals, Inc. -- 8-K 1.01: Merger Agreement
Jun 11
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An executive received accelerated equity vesting upon change of control, suggesting potential acquisition talks that could drive near-term stock appreciation if a deal closes.
Apr 9
8-K
Adial Pharmaceuticals, Inc -- 8-K Filing
Adial Pharmaceuticals reported 2025 fiscal year results and provided a business update, though specific financial details and guidance were not disclosed in this summary filing.
Mar 6
8-K · 8.01
!! High
Adial Pharmaceuticals, Inc -- 8-K 8.01: Material Event / Announcement
Adial Pharmaceuticals' February 2026 shareholder meeting failed to achieve quorum, preventing any stockholder votes and likely requiring rescheduling of critical business matters.
Mar 3
8-K · 8.01
!! High
Adial Pharmaceuticals, Inc -- 8-K 8.01: Material Event / Announcement
Adial Pharmaceuticals regained Nasdaq compliance after meeting minimum bid price requirements, resolving a delisting threat and allowing continued trading on the exchange.
Feb 24
8-K · 8.01
!! High
Adial Pharmaceuticals, Inc -- 8-K 8.01: Material Event / Announcement
Adial Pharmaceuticals executed a 1-for-25 reverse stock split to restore Nasdaq compliance by raising its stock price above the required $1.00 minimum bid threshold.
Feb 4
Institutional (13F) — Top 8
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 29,547 | $76K | New | Jun 2026 |
| 2 | Vanguard Capital Management Llc | 5,831 | $15K | Added | Jun 2026 |
| 3 | Ubs Group Ag | 542 | $970 | New | Mar 2026 |
| 4 | Blackrock, Inc. | 304 | $778 | New | Jun 2026 |
| 5 | Raffa Wealth Management, Llc | 83 | $212 | New | Jun 2026 |
| 6 | Sbi Securities Co., Ltd. | 47 | $120 | New | Jun 2026 |
| 7 | Wells Fargo & Company/mn | 6 | $11 | New | Mar 2026 |
| 8 | Abound Wealth Management | 1 | $3 | — | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 5,277 | $13K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 310 | $744 | May 2026 |
Valuation
Market Cap
$4.8M
Enterprise Value
-$2.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.01x
P/B
0.64x
P/S
—
P/FCF
-0.51x
EV/EBITDA
—
Shares Out
669K
Financials (TTM)
Revenue
$0
Net Income
-$7.8M
EBITDA
-$7.8M
Free Cash Flow
-$6.5M
Op Cash Flow
-$6.5M
EPS Basic
$-11.93
EPS Diluted
$-9.78
EPS Forward
$-6.12
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$6.7M
Total Liab.
$1.4M
Total Equity
$5.3M
Cash
$5.9M
LT Debt
$0
Book Value/Sh
$7.89
Debt/Equity
0.00x
Current Ratio
4.42
Quick Ratio
4.42
Returns & Growth
ROE
-151.2%
ROA
-119.5%
ROIC
-147.8%
Rev Growth YoY
+0.0%
EPS Growth YoY
+32.8%
Price Returns
2W
+37.1%
1M
+78.2%
3M
+209.9%
6M
+85.5%
12M
-47.5%
Technicals
52W High
$10.75
52W Low
$1.31
50d MA
$3.06
200d MA
$3.88
RSI (14)
72.70
ATR (14)
$0.55
Beta
1.40
Avg Volume
60K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$8.00
High
$8.00
Low
$8.00
Median
$8.00
Data updated apr 24, 2026 10:56am
· Source: financialmodelingprep.com